OBJECTIVES: Feasibility study to evaluate the efficacy and safety of Adjustable Transobturator Male System (ATOMS) after failed surgical devices for male stress urinary incontinence (SUI). MATERIALS AND METHODS: Thirty patients were implanted with ATOMS after they were implanted with surgical device/s previously. SUI severity was evaluated as dryness (0-1 pad/day), mild (2 pads/day), moderate (3-5 pads/day), or severe (≥6 pads/day). Change in pad-test and pad-count after adjustment, operative parameters, patient satisfaction, and number and grade of complications were investigated. RESULTS: Previous failed treatment methods were artificial urinary sphincter (AUS; n = 19), Advance (n = 10), and Virtue (n = 1). Six cases had multiple previous treatments. Preoperative SUI was mild 6 (20%), moderate 11 (36.7%), and severe 13 (43.3%). Median pad-test decreased from 435 mL baseline to 10 mL after adjustment and pad-count from 4 to 0. Dry-rate was 76.7 and 83.3% declared satisfied. Postoperative SUI distribution was mild in 3 (10%) and moderate in 4 (13.3%). No patient had urinary retention after catheter removal. Complications presented in 4 (13.3%; 3 grade-I, 1 grade-II). After a median of 24 months follow-up, no system experienced infection or urethral erosion and 1 (3.3%) was removed for inefficacy. CONCLUSION: Based on short-term efficacy and patient satisfaction, ATOMS can be a realistic alternative for male SUI after other failed systems, including AUS. The absence of urethral erosion and limited infective problems makes this alternative attractive for cases with previous failed treatments.
OBJECTIVES: Feasibility study to evaluate the efficacy and safety of Adjustable Transobturator Male System (ATOMS) after failed surgical devices for male stress urinary incontinence (SUI). MATERIALS AND METHODS: Thirty patients were implanted with ATOMS after they were implanted with surgical device/s previously. SUI severity was evaluated as dryness (0-1 pad/day), mild (2 pads/day), moderate (3-5 pads/day), or severe (≥6 pads/day). Change in pad-test and pad-count after adjustment, operative parameters, patient satisfaction, and number and grade of complications were investigated. RESULTS: Previous failed treatment methods were artificial urinary sphincter (AUS; n = 19), Advance (n = 10), and Virtue (n = 1). Six cases had multiple previous treatments. Preoperative SUI was mild 6 (20%), moderate 11 (36.7%), and severe 13 (43.3%). Median pad-test decreased from 435 mL baseline to 10 mL after adjustment and pad-count from 4 to 0. Dry-rate was 76.7 and 83.3% declared satisfied. Postoperative SUI distribution was mild in 3 (10%) and moderate in 4 (13.3%). No patient had urinary retention after catheter removal. Complications presented in 4 (13.3%; 3 grade-I, 1 grade-II). After a median of 24 months follow-up, no system experienced infection or urethral erosion and 1 (3.3%) was removed for inefficacy. CONCLUSION: Based on short-term efficacy and patient satisfaction, ATOMS can be a realistic alternative for male SUI after other failed systems, including AUS. The absence of urethral erosion and limited infective problems makes this alternative attractive for cases with previous failed treatments.
Authors: Javier C Angulo; Sonia Ruiz; Martín Lozano; Ignacio Arance; Miguel Virseda; David Lora Journal: World J Urol Date: 2020-06-11 Impact factor: 4.226
Authors: Javier C Angulo; Ignacio Arance; Antonio Ojea; Manuel Carballo; Andrés Rodríguez; Javier Pereira; Miguel Rebassa; Antoine Teyrouz; Gregorio Escribano; Fernando Teba; Blanca Madurga; Francisco E Martins; Francisco Cruz Journal: World J Urol Date: 2019-01-16 Impact factor: 4.226
Authors: Fabian Queissert; Keith Rourke; Sandra Schönburg; Alessandro Giammò; Andreas Gonsior; Carmen González-Enguita; Antonio Romero; Andres J Schrader; Francisco Cruz; Francisco E Martins; Juan F Dorado; Javier C Angulo Journal: J Clin Med Date: 2021-12-24 Impact factor: 4.241
Authors: Ane Ullate; Ignacio Arance; Miguel Virseda-Chamorro; Sonia Ruiz; Juliusz Szczesniewski; Carlos Téllez; Fabian Queissert; Juan F Dorado; Javier C Angulo Journal: J Clin Med Date: 2022-08-19 Impact factor: 4.964
Authors: Javier C Angulo; Sandra Schönburg; Alessandro Giammò; Francisco J Abellán; Ignacio Arance; David Lora Journal: PLoS One Date: 2019-12-02 Impact factor: 3.240